Articles

Trump’s CMS to Allow Skimpier Plans on ACA Exchanges: Implications for Pharma

This article examines the recent CMS changes under Trump that permit skimpier plans on ACA exchanges and their potential impact on the pharmaceutical sector.

Supreme Court Declines to Hear Drugmakers' IRA Cases

The Supreme Court's decision not to hear drugmakers' IRA cases raises significant questions for the pharmaceutical industry. This article explores the implications for business and investment strategies.

Driving Impact: The Role of Medical Affairs in Pharmaceutical Launches

This article delves into the critical role of medical affairs in pharmaceutical launches, highlighting its impact on business strategies and market success.

Eli Lilly's Community Engagement: A Strategic Move in Pharma Marketing

Eli Lilly collaborates with Caitlin Clark to revitalize sports courts in Indianapolis neighborhoods, highlighting a unique approach to community engagement. This initiative may reshape pharma marketing strategies.

Regeneron's Phase 3 Skin Cancer Trial Failure: Implications for LAG-3

Regeneron's recent Phase 3 trial failure for skin cancer highlights significant challenges in LAG-3 research. This article explores the implications for the pharmaceutical landscape.

BioMarin's Rare Disease Therapy Phase 3 Results: A Closer Look

BioMarin's recent Phase 3 test results reveal no clinical benefit for its rare disease therapy. This article explores the implications for the pharmaceutical landscape.

Ebola Outbreak: Experts Consider Unapproved Vaccine Testing

As the Ebola outbreak continues, experts are evaluating the potential of unapproved vaccines. This article discusses the implications for the pharmaceutical industry.

White House Collaborates with Amazon, GoodRx, and Mark Cuban on TrumpRx Initiative

The White House's partnership with Amazon, GoodRx, and Mark Cuban aims to enhance the TrumpRx initiative, impacting the pharmaceutical landscape. This article delves into the implications for pharma teams and stakeholders.

Maryland Caps Ozempic Prices: Implications for Pharma

Maryland's affordability board has placed a price cap on Ozempic, raising questions about its impact on the pharmaceutical landscape. This article explores the implications for industry stakeholders.

Amgen's Tavneos: Navigating Liver Toxicity Reports in Japan

Amgen stands firm on Tavneos despite liver toxicity concerns in Japan. This article explores the implications for pharma stakeholders.

Navigating Ghost Approval in Heart Transplant Medications

This article discusses the challenges faced by heart transplant recipients regarding medication approvals and the implications for the pharmaceutical industry.

Impact of Alcohol Consumption During Pregnancy on Pharma

This article examines the alarming statistic that 1 in 8 women consume alcohol during pregnancy and its potential consequences for the pharmaceutical industry.

The Impact of Ghost Approval on Heart Transplant Medications

This article examines the haunting issue of ghost approval for essential heart transplant medications from a recipient's perspective, highlighting investment implications.

The Latest on Ebola: Travel Ban and Old Vaccine Insights

This article delves into the recent travel ban related to Ebola and the implications of using an old vaccine, providing insights for pharmaceutical professionals.

The Alarming Impact of Alcohol Consumption During Pregnancy

A recent STAT+ report reveals that 1 in 8 women consume alcohol during pregnancy, raising concerns among experts about potential consequences for fetal health and the pharmaceutical sector.

Nourish Secures $100M for Virtual Nutrition Care Expansion

Nourish has successfully raised $100 million to expand its virtual nutrition care services. This significant investment highlights the growing importance of nutrition in healthcare.

Relay Drug Shows Early Promise Against Rare Blood Vessel Diseases

Relay's drug demonstrates early efficacy in treating rare blood vessel diseases, signaling potential market opportunities and investment implications.

Nourish Secures $100M for Virtual Nutrition Care: What It Means for Pharma

Nourish has raised $100M to enhance virtual nutrition care. This funding could reshape the landscape for pharmaceutical companies focusing on nutrition.

The Dangers of Ghost Approval in Heart Transplant Medication

This article discusses the challenges faced by heart transplant recipients regarding medication approvals and the broader implications for the pharmaceutical industry.

Full-Life Technologies Secures $150M; Quince's New Pulmonary Drug Strategy

Full-Life Technologies has successfully raised $150 million to advance its initiatives, while Quince is rebooting its strategy with a new pulmonary drug. This article explores the implications for the pharmaceutical industry.